In that way, initiatives such as N2M2 (NOA-20) phase I/II trial (NCT03158389) of molecularly matched targeted therapies plus radiotherapy in GBM patients, with an unmethylated MGMT promoter, appears of great interest [71]. This evidence concerns the gene MGMT and glioblastoma.